PMID- 36277708
OWN - NLM
STAT- MEDLINE
DCOM- 20221025
LR  - 20221026
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Dose-response relationship between Chinese visceral adiposity index and type 2 
      diabetes mellitus among middle-aged and elderly Chinese.
PG  - 959860
LID - 10.3389/fendo.2022.959860 [doi]
LID - 959860
AB  - INTRODUCTION: China has the largest population of diabetic patients (about 116 
      million) in the world. As a novel model of the fat index for Chinese people, the 
      Chinese visceral adiposity index (CVAI) was considered a reliable indicator to 
      assess the dysfunction of visceral fat. This study aimed to explore the 
      dose-response relationship between CVAI and type 2 diabetes mellitus (T2DM) in 
      the Chinese population, considering CVAI as a continuous/categorical variable. 
      METHOD: Baseline and follow-up data were collected from waves 2011 and 2015, 
      respectively, of the China Health and Retirement Longitudinal Study (CHARLS). 
      Multivariate logistic regression models were used to explore the relationship 
      between CVAI and T2DM. We built three models to adjust the possible effect of 10 
      factors (age, gender, education level, location, marital status, smoking status, 
      drinking status, sleep time, systolic blood pressure (SBP), and diastolic blood 
      pressure (DBP)) on the outcome. The restricted cubic splines were used to examine 
      possible non-linear associations and visualize the dose-response relationship 
      between CVAI and T2DM. RESULTS: A total of 5,014 participants were included, with 
      602 (12.00%) T2DM patients. The last CVAI quartile group (Q4) presented the 
      highest risk of T2DM (OR, 2.17, 95% CI, 1.67-2.83), after adjusting for all 
      covariates. There was a non-linear (U-shaped) relationship between the CVAI and 
      the risk of T2DM (p for non-linear <0.001) in the restricted cubic spline 
      regression model. CVAI was a risk factor of T2DM when it exceeded 92.49; every 
      interquartile range (IQR) increment in the CVAI was associated with a 57% higher 
      risk of developing T2DM (OR = 1.57, 95% CI = 1.36-1.83) after adjusting for 
      potential confounders. The area under the receiver operating characteristic curve 
      (AUC) (95% confidence interval) for CVAI was 0.623, and the optimal cutoff point 
      was 111.2. There was a significant interaction between CVAI and gender by 
      stratified analysis. CONCLUSION: CVAI was closely associated with the risk of 
      T2DM and might possibly be a potential marker in predicting T2DM development. The 
      outcome suggested that it might be better to maintain CVAI within an appropriate 
      range.
CI  - Copyright (c) 2022 Pan, Xu, Liu, Gao, Li, Peng, Chen, Wang, Mai and Yang.
FAU - Pan, Liang
AU  - Pan L
AD  - Phase 1 Clinical Trial Center, Deyang People's Hospital, Deyang, China.
FAU - Xu, Qianqian
AU  - Xu Q
AD  - Department of Medical Imaging Center, Zhongnan Hospital of Wuhan University, 
      Wuhan, China.
FAU - Liu, Jianmin
AU  - Liu J
AD  - Department of Otolaryngology and Head and Neck Surgery, Deyang People's Hospital, 
      Deyang, China.
FAU - Gao, Yang
AU  - Gao Y
AD  - Department of Pediatrics , Deyang People's Hospital, Deyang, China.
FAU - Li, Jun
AU  - Li J
AD  - Department of Nephrology , Deyang People's Hospital, Deyang, China.
FAU - Peng, Hongye
AU  - Peng H
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Chen, Linli
AU  - Chen L
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Wang, Miyuan
AU  - Wang M
AD  - School of Public Health, Huazhong University of Science and Technology, Wuhan, 
      China.
FAU - Mai, Gang
AU  - Mai G
AD  - Phase 1 Clinical Trial Center, Deyang People's Hospital, Deyang, China.
FAU - Yang, Shuo
AU  - Yang S
AD  - Central Laboratory, HuangGang Hospital of Traditional Chinese Medicine (TCM), 
      Huanggang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221005
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Middle Aged
MH  - Aged
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/etiology/complications
MH  - Adiposity
MH  - Longitudinal Studies
MH  - Obesity, Abdominal/complications/epidemiology
MH  - China/epidemiology
PMC - PMC9579311
OTO - NOTNLM
OT  - chinese visceral adiposity index
OT  - dose-response relationship
OT  - prospective cohort study
OT  - restricted cubic spline regression
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/25 06:00
MHDA- 2022/10/26 06:00
PMCR- 2022/01/01
CRDT- 2022/10/24 04:37
PHST- 2022/06/02 00:00 [received]
PHST- 2022/09/14 00:00 [accepted]
PHST- 2022/10/24 04:37 [entrez]
PHST- 2022/10/25 06:00 [pubmed]
PHST- 2022/10/26 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.959860 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Oct 5;13:959860. doi: 
      10.3389/fendo.2022.959860. eCollection 2022.